Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Indo-Bangla Pharmaceuticals's Net Income for the
six
months ended in . 20 was BDT0.00 Mil. Its Net Income for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.
Indo-Bangla Pharmaceuticals (DHA:IBP) Net Income Explanation
Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
Indo-Bangla Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable business
Consistent accounting methods
And few restructurings
The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Indo-Bangla Pharmaceuticals Net Income Related Terms
Indo-Bangla Pharmaceuticals Net Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals Net Income Calculation
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Net Income of BDT0.00 Mil as of . 20. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Net Income too high?
Indo-Bangla Pharmaceuticals' current Net Income is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Net Income compare to ?
Indo-Bangla Pharmaceuticals' Net Income of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Drug Manufacturers company?
A good Net Income depends on the Drug Manufacturers industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Net Income is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Net Income of BDT0.00 Mil. The current Net Income is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Net Income is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score
Get the complete analysis for DHA:IBP
Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBP has been successfully added to your 
